miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib

Table 2

Validation of miR-155 and miR-484 on the independent cohort () and their correlation with TTP (months).

	Number of patients ()	Median TTP (months)	Log-rank	HR	95% CI
miR-155
Low, <0.2381	42	12.8	0.0092	2.412	1.243–4.680
High, ≥0.2381	21	5.8
miR-484
Low, <1.4408	52	8.9	0.0296	2.623	1.100–6.254
High, ≥1.4408	11	5.8